A possible explanation is that the attenuation of the CD8 T cell function by Ezh2 inhibition is overcome by DNMT inhibitor induced immunostimulatory factors, such as CXCL9 and 10, in the tumor microenvironment. The gene discussed is DNMT1; the disease is neoplasm.